Who Generates More Revenue? Exelixis, Inc. or Cytokinetics, Incorporated

Exelixis leads revenue growth over Cytokinetics in biotech race.

__timestampCytokinetics, IncorporatedExelixis, Inc.
Wednesday, January 1, 20144694000025111000
Thursday, January 1, 20152865800037172000
Friday, January 1, 2016106407000191454000
Sunday, January 1, 201713368000452477000
Monday, January 1, 201831501000853826000
Tuesday, January 1, 201926868000967775000
Wednesday, January 1, 202055828000987538000
Friday, January 1, 2021704280001434970000
Saturday, January 1, 2022945880001611062000
Sunday, January 1, 202375300001830208000
Monday, January 1, 20242168701000
Loading chart...

Infusing magic into the data realm

Revenue Race: Exelixis vs. Cytokinetics

In the competitive landscape of biotechnology, revenue generation is a key indicator of success. Over the past decade, Exelixis, Inc. and Cytokinetics, Incorporated have been at the forefront of this race. From 2014 to 2023, Exelixis has consistently outperformed Cytokinetics, with a staggering 1,830% increase in revenue by 2023. In contrast, Cytokinetics saw a more modest growth, peaking in 2016 with a 126% increase from the previous year, but experiencing fluctuations thereafter.

Exelixis's revenue surged notably in 2017, marking a pivotal year with a 136% increase from 2016, and continued to climb, reaching its zenith in 2023. Meanwhile, Cytokinetics faced a decline in 2023, dropping to just 7% of its 2016 peak. This data highlights the dynamic nature of the biotech industry and the varying strategies companies employ to drive growth.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025